Safety, pharmacokinetics and sialic acid production after oral administration of N -acetylmannosamine (ManNAc) to subjects with GNE myopathy
Xin Xu(National Institutes of Health), Nuria Carrillo(National Institutes of Health), Selwyn C. Yorke(Pharmac), John C. McKew(National Institutes of Health), James C. Cradock(National Institutes of Health), May Christine V. Malicdan(National Institutes of Health), Pramod Terse(National Institutes of Health), Frank Celeste(National Institutes of Health), Barry R. Goldspiel(National Institutes of Health Clinical Center), Lea Latham(National Institutes of Health), William A. Gahl(National Institute of Child Health), Marjan Huizing(National Human Genome Research Institute), N. Nora Yang(National Center for Advancing Translational Sciences), Carla Ciccone(National Institutes of Health), Amy Q. Wang(National Institutes of Health)
Cited by 67
Related Papers
Lysosomal storage diseases
|Translational Science of Rare Diseases|2016|261
Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs
|Emerging Microbes & Infections|2014|242
Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine
|Journal of Clinical Investigation|2007|202
The Undiagnosed Diseases Network: Accelerating Discovery about Health and Disease
|The American Journal of Human Genetics|2017|188